<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430846</url>
  </required_header>
  <id_info>
    <org_study_id>SG035-0001</org_study_id>
    <nct_id>NCT00430846</nct_id>
    <nct_alias>NCT00412282</nct_alias>
  </id_info>
  <brief_title>Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies</brief_title>
  <official_title>A Phase I Dose Escalation Study of SGN-35 in Patients With Relapsed/Refractory CD30-Positive Hematologic Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I study to define the safety profile and pharmacokinetic parameters of SGN-35 in
      patients with relapsed/refractory CD30-positive hematologic malignancies. This is a
      single-arm, open-label, Phase I dose escalation study designed to define the MTD, PK,
      immunogenicity and anti-tumor activity of SGN-35 in patients with relapsed/refractory
      CD30-positive hematologic malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events and laboratory abnormalities</measure>
    <time_frame>1 month after last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile</measure>
    <time_frame>2 months after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity (anti-SGN-35 antibodies)</measure>
    <time_frame>1 month after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>1 month after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Disease, Hodgkin</condition>
  <condition>Lymphoma, Large-Cell, Anaplastic</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-35</intervention_name>
    <description>Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg</description>
    <arm_group_label>A</arm_group_label>
    <other_name>brentuximab vedotin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed CD30-positive hematologic malignancy.

          -  Patients with HL must have failed systemic chemotherapy either as induction therapy
             for advanced stage disease or salvage therapy after initial radiotherapy for early
             stage disease and were ineligible for, refused treatment by, or previously received
             stem cell transplant.

          -  Patients must have measurable disease of at least 10mm as documented by radiographic
             technique.

          -  Must be at least 18 years of age.

        Exclusion Criteria:

          -  Patients with current diagnosis of pcALCL (systemic ALCL eligible).

          -  Patients with history of allogeneic stem cell transplant.

          -  Patients who have had previous treatment with any anti-CD30 antibody.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Forero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anas Younes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nancy Bartlett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Leonard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dana Kennedy, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ALCL.com</url>
  </link>
  <results_reference>
    <citation>Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965.</citation>
    <PMID>21047225</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2007</study_first_submitted>
  <study_first_submitted_qc>February 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2007</study_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antigens,CD30</keyword>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Lymphoma, Non-Hodgkin</keyword>
  <keyword>Disease, Hodgkin</keyword>
  <keyword>Lymphoma, Large-Cell, Anaplastic</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

